A5019641096- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Single-cell and spatial transcriptomics
- Cancer Genomics and Diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Click Chemistry and Applications
- Chemical Synthesis and Analysis
- Cancer-related gene regulation
KU Leuven
2019-2021
Universitair Ziekenhuis Leuven
2020
Vlaams Instituut voor Biotechnologie
2020
VIB-KU Leuven Center for Cancer Biology
2017-2019
Mutations in the interleukin-7 receptor (IL7R) or Janus kinase 3 (JAK3) occur frequently T-cell acute lymphoblastic leukemia (T-ALL) and both are able to drive cellular transformation development of T-ALL mouse models. However, signal transduction pathways downstream JAK3 mutations remain poorly characterized. Here we describe phosphoproteome JAK3(L857Q)/(M511I) activating transformed Ba/F3 lymphocyte cells. Signaling regulated by mutants were assessed following inhibition JAK1/JAK3 using...
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of the lymphocytes that driven by cooperation various mutations. Constitutive activation JAK-STAT signaling observed in one-third T-ALL patients and caused activating mutations interleukin 7 receptor alpha chain (IL7R), Janus kinases JAK1 or JAK3, Signal transducer activator transcription 5B (STAT5B).1–3 STAT5B are most frequently N642H variant associated with unfavorable prognosis higher risk relapse.1,2,4,5 We set out...
Abstract Background T cell acute lymphoblastic leukemia (T-ALL) is a high-risk subtype that comprises 10–15% of childhood and 20–25% adult ALL cases. Over 70% T-ALL patients harbor activating mutations in the NOTCH1 signaling pathway are predicted to be sensitive gamma-secretase inhibitors. We have recently demonstrated selective inhibition PSEN1-containing complexes can overcome dose-limiting toxicity associated with broad In this study, we developed combination treatment strategies...
Background: T‐cell acute lymphoblastic leukemia (T‐ALL) is an aggressive malignancy of the lymphocytes that mainly affects children. High cure rates can be achieved in pediatric T‐ALL at cost long‐term side‐effects conventional chemotherapy. Despite progress past years, remain below 50% adults and for refractory or relapsed patients prognosis remains dismal. Given over 60% carry activating mutations NOTCH1, mutant NOTCH1 requires cleavage by g‐secretase complex its oncogenic activity,...